Lv3
240 积分 2024-02-20 加入
Gut microbiome model predicts response to neoadjuvant immunotherapy plus chemoradiotherapy in rectal cancer
28天前
已完结
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
29天前
已完结
Minimal residual disease in colorectal cancer. Tumor-informed versus tumor-agnostic approaches: unraveling the optimal strategy
1个月前
已完结
A systematic review on the role of interventional radiotherapy for treatment of anal squamous cell cancer: multimodal and multidisciplinary therapeutic approach
1个月前
已关闭
Multidisciplinary Management of Anorectal Melanoma: a Retrospective Analysis of Surgical and Systemic Therapies from the National Cancer Database
2个月前
已完结
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population
4个月前
已完结
Rectal Cancer Update: Which Treatment Effects Are the Least “Brutal”?
5个月前
已完结
Hits and Misses in Novel Pancreatic and Rectal Cancer Treatment Options
5个月前
已完结
Gut microbiome model predicts response to neoadjuvant immunotherapy plus chemoradiotherapy in rectal cancer
5个月前
已完结
皖公网安备34019202002308
